Anti-Human CD195 (CCR5) – Purified in vivo GOLD™ Functional Grade
Anti-Human CD195 (CCR5) – Purified in vivo GOLD™ Functional Grade
Product No.: I-2501
- -
- -
Clone HEK/1/85a/7a Target CD195 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names C-C chemokine receptor type 5, CC-CKR-5, CCR-5, CHEMR13, HIV-1 fusion coreceptor Isotype Rat IgG2b κ Applications FC , ICC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen CHO cells transfected with full-length human CD195 (CCR5). Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893835 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this CD195 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? ICC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone HEK/1/85a/7a recognizes an epitope on human CCR5. Background CCR5 antibody, HEK/1/85a/7a, recognizes C-C chemokine receptor type 5 (CCR5), also known as CD195, CC-CKR-5, CHEMR13, and HIV-1 fusion coreceptor. CCR5 is a 45 kDa seven-transmembrane G-protein-coupled receptor (GPCR). CCR5 is expressed on a subset of memory T cells, macrophages, and immature dendritic cells (DCs) and is upregulated by proinflammatory cytokines1,2. CCR5 binds to inflammatory CC-chemokines, including CCL3 (macrophage inflammatory protein (MIP)-1α), CCL4 (MIP-1β), and RANTES, which increases intracellular calcium levels and results in cytoskeletal rearrangement and chemotactic cell migration3. CCR5 is also the coreceptor for HIV-1 following binding of viral gp120 to CD44-7. The levels of CCR5 on cells influence the rate of entry of HIV-1, and patients with lower levels of CCR5 exhibit immunity against infection8. CCR5 also contributes to other human diseases, including type I diabetes9 and cancer10. Antigen Distribution CCR5 is expressed on memory T cells, macrophages, and immature dendritic cells (DCs). NCBI Gene Bank ID References & Citations1. Mackay CR., et al. (1997) Proc Natl Acad Sci. 94(5):1925-30 2. Doms RW., et al. (1999) Proc Natl Acad Sci. 96(9):5215-5220 3. Parmentier M., et al. (1996) Biochemistry. 35(11):3362-7 4. Berger EA., et al. (1996) Science. 272(5270):1955-8 5. Sodroski J., et al. (1996) Cell. 1996 85(7):1135-48 6. Doms RW., et al. (1996) Cell. 85(7):1149-58 7. Paxton WA., et al. (1996) Nature. 381(6584):667-73 8. Sheppard HW., et al. (1997) Nat Med. 3(10):1160-2 9. Delovitch TL., et al. (2000) J Immunol. 165(2):1102-10 10. Casagrande N., et al. (2020) Cancers (Basel). 12(7):1765 Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
